


biotechne[®]

Corporate Presentation

January 2019



Safe Harbor

Cautionary Statements

This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, benefits of investments and partnerships, business strategies and other matters. Such statements can be identified by words such as: “expected,” “expects,” “expect,” “forecast,” “would,” “estimate,” “will,” or similar references to future periods.


Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see our latest Annual Report on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise.


This presentation also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For definitions of applicable non-GAAP financial measures and reconciliations of non-GAAP financial information to GAAP financial information, see the Reconciliations of GAAP to Non-GAAP Financial Measures included in the Company’s financial reports on Forms 10-Q and 10-K and related press releases.

At a Glance:


President and CEO: **Chuck Kummeth**
Headquarters: **Minneapolis, MN**
Number of Employees: **~2,100**
World Wide Presence: **35 Locations**
FY2018 Revenues: **\$643 million**
NASDAQ: **TECH**
Market Cap: **+\$5B**

Legacy Revenue






- Academia
- Pharma/Biotech
- Distributors
- OEM



Historical Organic Growth





Geographic Expansion



Core Product
Innovation




Gap Filling M&A and
Market Expansion



Culture Creation &
Talent

- Healthy hopper of targets
- Sound prioritization strategy
- Targets that fill gaps
- Targets with ROIC > WACC



for **EPIC** Tools
EPIC Science

Empowerment


Passion

Innovation

Collaboration


biotechne®

| Protein Sciences Segment | |
|--|--|
|  Reagent Solutions Develops and manufactures biological reagents used in all aspects of life science research |      |
|  Analytical Solutions Manual and automated protein analysis solutions that improve the efficiency of process work streams & quantitate secreted proteins |   |
| Diagnostics and Genomics Segment | |
|  Diagnostics Develops and manufactures controls, calibrators and diagnostic assays for the regulated diagnostic market |   |
|  Genomics Advanced, tissue morphology friendly RNA <i>in situ</i> hybridization (ISH) assay for transcriptome analysis & high value molecular diagnostics |   |



biotechne[®]

Protein Sciences Segment




ATLANTA biologicals
by **R&D SYSTEMS**



Specialty Media
Supplements


R&D SYSTEMS
a **biotechne** brand




Proteins




Bioprocessing
(Growth Factors for large
scale Production)




Cell Therapy
(GMP grade Proteins)



Cancer Immunotherapy Research
(Immune Checkpoint Proteins)








TOCRIS
a biotechne brand

Functions

- Inhibitors
- Activators
- Agonists
- Antagonists
- Blockers
- Modulators
- Ligands
- GMP Grade Reagents



Immunoassays: Different Users & Different Needs

Fully Validated

Quantikine®




Simple Plex™




DuoSet®



Arrays



Luminex®



Simple Western™



FluorChem
Alphamager



Single-Cell



Homemade Assays

Manual

Fully Automated



Imaging




Separation



Immunoassay




Microfluidics



Proteins have complex structures




Measurement





Analysis



Immune Cell Therapy Opportunities




Only releasable, non-magnetic cell selection technology



Directly-conjugated antibodies



Current RUO cell selection solution



**Coming
Soon!**


Revolutionizing the clinical workflow

Bringing automation and GMP-compliance to our magnetic bead-free cell separation



biotechne[®]

Diagnostics & Genomics Segment



Locations & Brands in Bio-Techne's Diagnostics and Genomics Segment



Calibration and control products

- General Chemistry
- Hematology
- Diabetes (Blood glucose, HbA1c)
- Blood Gas/Electrolytes
- Immunochemistry
- Urine Chemistry/Urinalysis
- Coagulation



Biological components & Tests

- Cardiac Markers
- Lipids
- Specific Proteins
- Cancer Markers
- Toxicology
- TDM
- DOA





Instrument companies

- Point of Care




- Laboratory instrumentation






DNA
FISH 1990s



RNA
RNAscope® 2012



Protein
IHC 1970s

- **Advanced Cell Diagnostics**
- Technology allows both manual and automated gene expression analysis
- Optimized for single and multiplex analysis
- >15,000 off-the-shelf target probes
- RNAscope and BaseScope are current assays on the market
- Pharma Assay Services further deploys the technology to select customers
- Represents the most advanced RNA in situ hybridization (ISH) assay for transcriptome analysis and gene quantitation while retaining tissue morphology




RNAscope



VENTANA



LEICA




| Key Properties | CTCs | cfDNA | Exosomes |
|-----------------------------------|---------------------------------------|---|-----------------------|
| Frequency | Infrequent in early stages of disease | Difficult to find within "noise" of contaminating DNA | Abundant |
| Ability to Enrich or Select | Yes | No | Yes |
| Quality of Isolated Nucleic Acids | Good | Poor due to enzymes exposure | High quality-shielded |


Intended Use:

The EPI™ risk score is used to risk stratify likelihood of high grade ($GS \geq 7$) prostate cancer on initial biopsy in men 50-years and older, with a PSA 2-10ng/mL.

The Workflow:





Technically and Clinically Validated Tests Drive Rapid Commercial Expansion



2017

2022



| | |
|---|-----------------|
| | <u>Rev CAGR</u> |
| • Analytical Solutions | +15-20% |
| • Reagent Solutions | +5-7% |
| <hr/> | |
| Protein Sciences Segment | +8-11% |
| • Diagnostics | +4-6% |
| • Genomics -- ACD | +20-30% |
| • Genomics – ExoDx | ~ \$150mm |
| <hr/> | |
| Diagnostics & Genomics Segment | ~ +20% |

| | |
|---|--------------------|
| | <u>OM% in 5yrs</u> |
| • Analytical Solutions | ~ 30% |
| • Reagent Solutions | +50% |
| <hr/> | |
| Protein Sciences Segment | mid 40s% |
| • Diagnostics | ~ 30% |
| • Genomics -- ACD | mid 30s% |
| • Genomics – ExoDx | ~ 30% |
| <hr/> | |
| Diagnostics & Genomics Segment | low 30s% |

* All figures are expressed in millions.
 ** Assumes no further unannounced acquisitions



North America, Europe, and Asia

>300,000
Products



Our brands bring you >300,000 quality products

~2,100
Employees



Nearly 2,100 employees globally

>40
Years



Our companies have been manufacturing and sourcing reagents for more than 40 years

>500,000
Citations



Generated using our products

6
Platforms



6 instrument platforms that leverage biological content